Precision Medicine

Kairos Pharma Secures Exclusive Global Rights to Promising AI-Designed EGFR Inhibitor CL-273 in Strategic Acquisition Deal

by
Microscopic view of lung cancer cells with EGFR mutations targeted by innovative inhibitor therapy

“Kairos Pharma, a clinical-stage biopharmaceutical company listed on the NYSE American under the ticker KAPA, has entered into binding terms to acquire exclusive worldwide rights to CL-273, an investigational pan-EGFR inhibitor developed by Celyn Therapeutics. This AI-designed, wild-type-sparing compound targets EGFR-mutant non-small cell lung cancer (NSCLC), addressing key resistance challenges in a market valued at … Read more

Athos Therapeutics Secures FDA Green Light for Phase 2 Trial of Innovative ATH-063 in Ulcerative Colitis Battle

by
Medical illustration of gut inflammation and healing process in ulcerative colitis

“Athos Therapeutics has obtained FDA clearance to launch a Phase 2 clinical trial for ATH-063, an AI-engineered oral small molecule aimed at treating moderate to severe ulcerative colitis in patients unresponsive to biologics. The drug targets inflammation and mucosal healing, building on successful Phase 1 outcomes that validated the company’s AI platform. This multi-center study … Read more